Armata reports diSArm trial 80% enrolled, AP-PA02 topline data Sep 2024; Phase 3 planned for 2025

Armata Pharmaceuticals, Inc.

diSArm Phase 1b/2a for AP-SA02 (S. aureus bacteremia) now 80% enrolled; completion expected Q4 2024.
AP-PA02 (P. aeruginosa bronchiectasis) enrollment completed; topline data expected September 2024.
Intravenous AP-SA02 and inhaled AP-PA02 well tolerated; early data show phage activity and persistence.
Phage candidates planned to enter pivotal Phase 3 trials in 2025, supported by $21.6M DoD grant.
Inhaled AP-PA02 monotherapy showed comparable to better bacterial load reduction vs antibiotics in blinded data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.